RESUMEN
Objective:To explore the infection of Toxoplasma gondii in patients with common gynecological malignancies and to explore the correlation between gynecological malignancies and Toxoplasma gondii infection, so as to provide basis for the prevention and control of Toxoplasma gondii infection in such population in the future. Methods:Patients with gynecological malignancies (114 cases of ovarian cancer, 107 cases of cervical cancer and 110 cases of endometrial cancer) treated in Shengjing Hospital of China Medical University from January 2018 to January 2020 were selected as the study group, and 200 women with normal physical examination during the same period were selected as the control group.Enzyme linked immunosorbent assay was used to detect serum anti Toxoplasma gondii IgM and IgG antibodies in the two groups. Results:The overall Toxoplasma gondii infection rate and the overall serum anti- Toxoplasma gondii IgG antibody positive rate in the study group were 26.89%(89/331) and 26.28%(87/331), respectively, which were higher than 5.00%(10/200) of the control group, and the results were significantly different( χ2 values were 39.32, 37.73, P<0.01). The positive rates of anti- Toxoplasma gondii IgG antibody in patients with ovarian cancer, cervical cancer and endometrial cancer of the study group were 28.07%(32/114), 25.23%(27/107) and 25.45%(28/110), respectively, which were higher than those in the control group (5.00%,10/200)( χ2 values were 32.26, 27.32, 28.00, all P<0.01). Conclusions:The positive rate of Toxoplasma gondii infection in gynecological malignant tumor patients with low immune function is high, which should be paid enough attention by medical staff to strengthen the prevention and control of infection.
RESUMEN
The age of onset of gynecological malignant tumors tends to be younger,more and more patients have fertility requirements when they are diagnosed with cancer.Different cancer treatments have a certain impact on the fertility of patients, application of assisted reproductive technology(ART)can help part of the patients fulfill their fertility wish. In this paper, the methods and safety of ART for three gynecological malignant tumors are discussed.
RESUMEN
Objective To investigate the seroprevalence of Toxoplasma gondii infection in patients with gynecological malignant tumors, so as to provide the evidence for the control of T. gondii infections in the patients with gynecological malignant tumors. Methods A total of 327 patients with gynecological malignant tumors were recruited, and 200 women with normal healthy examinations were served as controls. The serum anti-T. gondii IgG and IgM antibodies were detected by using ELISA, and the seroprevalence was compared between the patients and controls, and among various types of cancers. Results The overall seroprevalence of T. gondii was 26.91% (88/327) in the patients with gynecological malignant tumors, which was significantly higher than that (5.00%) in the healthy volunteers (χ2 = 39.36, P<0.01) . The prevalence of anti-T. gondii IgG antibody in the cancer patients was significantly higher than that in the controls (26.30% vs. 5.00%; χ2 = 37.79, P<0.01), while the prevalence of anti-T. gondii IgM antibody in the cancer patients was not significantly different from that in the controls (0.92% vs. 0; corrected χ2 = 0.58, P > 0.01) . The positive rates of anti-T. gondii IgG antibody were 27.68%, 25.47% and 25.69% in ovarian cancer, cervical cancer, and breast cancer patients respectively, which were all significantly higher than those in the controls (χ2 = 32.35, 27.32 and 28.00; all P values<0.01); however, there was no significant difference among the various types of cancer patients in the positive rates of anti-T. gondii IgG antibody (χ2 = 0.17, P > 0.05) . In addition, the positive rates of anti-T. gondii IgM antibody were 1.79%, 0 and 0.92% in ovarian cancer, cervical cancer and breast cancer patients respectively, which was not significantly different from those in the controls (all P values > 0.05). Conclusions The seroprevalence of T. gondii infection is high in the patients with gynecological malignant tumors. It is suggested that the prevention and control of T. gondii infection should be strengthened in these patients.
RESUMEN
Objective To investigate the seroprevalence of Toxoplasma gondii infection in patients with gynecological malignant tumors, so as to provide the evidence for the control of T. gondii infections in the patients with gynecological malignant tumors. Methods A total of 327 patients with gynecological malignant tumors were recruited, and 200 women with normal healthy examinations were served as controls. The serum anti-T. gondii IgG and IgM antibodies were detected by using ELISA, and the seroprevalence was compared between the patients and controls, and among various types of cancers. Results The overall seroprevalence of T. gondii was 26.91% (88/327) in the patients with gynecological malignant tumors, which was significantly higher than that (5.00%) in the healthy volunteers (χ2 = 39.36, P<0.01) . The prevalence of anti-T. gondii IgG antibody in the cancer patients was significantly higher than that in the controls (26.30% vs. 5.00%; χ2 = 37.79, P<0.01), while the prevalence of anti-T. gondii IgM antibody in the cancer patients was not significantly different from that in the controls (0.92% vs. 0; corrected χ2 = 0.58, P > 0.01) . The positive rates of anti-T. gondii IgG antibody were 27.68%, 25.47% and 25.69% in ovarian cancer, cervical cancer, and breast cancer patients respectively, which were all significantly higher than those in the controls (χ2 = 32.35, 27.32 and 28.00; all P values<0.01); however, there was no significant difference among the various types of cancer patients in the positive rates of anti-T. gondii IgG antibody (χ2 = 0.17, P > 0.05) . In addition, the positive rates of anti-T. gondii IgM antibody were 1.79%, 0 and 0.92% in ovarian cancer, cervical cancer and breast cancer patients respectively, which was not significantly different from those in the controls (all P values > 0.05). Conclusions The seroprevalence of T. gondii infection is high in the patients with gynecological malignant tumors. It is suggested that the prevention and control of T. gondii infection should be strengthened in these patients.
RESUMEN
Objective To analyze the pathogenesis and prevention and treatment of limb deep venous thrombosis complicated by postoperative gynaecological malignant tumours.Methods A retrospective analysis of 22 cases with limb deep venous thrombosis complicated by postoperative gynaecological malignant tumours in our hospital were analyzed.According to the situation of patients,surgery or conservative treatment was conducted.The clinical efficacy after treatment was observed.Results In 22 cases,6 cases underwent surgical treatment,16 cases underwent conservative treatment.After treatment,18 cases were cured,3 cases were effective,1 case ineffective.After treatment,the TT,Pt,APTT and FBG levels were (24.17 ±2.13)s,(18.25 ±2.13)s,(31.68 ± 10.30)s and (2.26 ±0.52) g/L,which were all better than before treatment,the differences were statistically significant (t =10.362,9.774,12.281,8.462,P =0.028,0.032,0.012,0.029).Followed up for 3 months,no recurrence of LDVT was observed.Conclusion The cases of gynecological malignant tumor have higher risk of limb deep vein thrombosis,we should taken prevention actively,once diagnosed should take effective intervention measures to improve the prognosis.
RESUMEN
Objective To observe the association between clinical pharmacokinetic of paclitaxel and adverse reactions in patients with gynecological malignant tumor.Methods 78 patients with female malignant tumor selected from Jan.2009 to Dec.2013 in Kailuan General Hospital were treated with paclitaxel (intravenous drip 175 mg/m2 3 h).The blood drug level of paclitaxel was measured at different time after treating.The DAS software was used to calculate the parameter of pharmacokinetic of paclitaxel,and the SPSS software was used to analyze the association between clinical pharmacokinetic of paclitaxel and adverse reaction in patients with female malignant tumor.Results The peak plasma concentrations (Cmax)was (3.99 ± 1.07)mg/L,the areas under the plasma concentration-time curve (AUC)was (9.74 ±2.45)mg/(h·L),the plasma elimination half-life (t1/2z)was (13.7 ±3.2)h,the apparent volumes of distribution (Vd)was (162.9 ±49.5)L/m2,the plasma clearance rates (CL)was (8.2 ±1.0)L/(h·kg).The kinetics of paclitaxel was fitted to two-compartment model.The time of drug concentration >0.1 μmol/L (t>0.1 )in responder patients (16.8 ± 4.8)h was higher than that in nonresponder patients (13.5 ±2.9)h,and the difference was significant (P<0.05).The Cmax in patients with severity adverse reactions (4.61 ±0.86)mg/L were higher than those in patients without severity adverse reaction (3.65 ±1.13)mg/L,and the difference was significant (P<0.01).Conclusion The Cmax of paclitaxel is associated with efficacy after treatment and severity adverse reactions.
RESUMEN
Objective: To investigate the psychosocial characteristics and mind-physique status of pa-tients with gynecological malignant tumors. Methods: Clinical psycho-rating scale [life event scale (LES) and symptom checklist-90 (SCL-90)] was applied to test life events and mind-physique status of 60 cases of pa-tients with gynecological malignant tumor. The results were compared with those of 40 female patients with benign tumors and 40 normal females. Results: The frequency and tension value of total life events and those of negative life events in the malignant cancer group were much higher than those in the benign tumor group and normal group (P<0.05) and no remarkable differences were found in the frequency of positive life events among the three groups. The frequencies of total life events and negative life events were higher in the be-nign tumor group than those in the normal group (P<0.05) but there were no significant differences in the fre-quency of positive life events, total tension value or positive tension value among the three groups. No signifi-cant differences were found in the indices of SCL-90, positive scores and scorns of other factors among the three groups (P>0.05). The scores of somatization, obsession, interpersonal relationship sensitivity, anxiety, hostility, phobia, and paranoia were higher in the malignant tumor group than in the benign tumor group and normal group (P<0.05). The average positive scores and the depression scores in the benign tumor group were higher than those in the normal group (P<0.05), but there was no statistical significance in other indices between the benign tumor group and the normal group (P>0.05). Conclusion: Negative psychosocial factors are closely correlated with the occurrence and growth of gynecological malignant tumors. Active psychological intervention should be performed as eady as possible.